This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): GT160-246 tolevamer toxin binder, GT267-004
Description: Tolevamer is a binder for the toxin produced by Clostridium difficile (C. difficile). When antibiotic use destroys the normal gastrointestinal bacterial flora, C. difficile, which is there normally, can proliferate and release toxin, causing C. difficile associated disease (CDAD).
Tolevamer, like two other polymer therapies developed by Genzyme, Renagel (sevelamer hydrochloride) and WelChol (colesevelam hydrochloride), acts in the gastrointestinal tract to bind and remove unwanted substances.
Deal Structure: In October 2010, Sanofi-aventis announced it has commenced a tender offer for all outstanding shares of common stock of Genzyme for $69 per share, net to the seller in cash, without interest and less any required withholding taxes. In April 2011, Sanofi-aventis announced that it successfully completed its exchange offer for all outstanding shares of common stock of Genzyme Corporation.
Additional information available to subscribers only: